Trials / Completed
CompletedNCT00005921
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
Detailed description
In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | L-743,872 |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00005921. Inclusion in this directory is not an endorsement.